Tyra disappoints investors with bladder cancer data
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.